JP2017530984A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017530984A5 JP2017530984A5 JP2017518802A JP2017518802A JP2017530984A5 JP 2017530984 A5 JP2017530984 A5 JP 2017530984A5 JP 2017518802 A JP2017518802 A JP 2017518802A JP 2017518802 A JP2017518802 A JP 2017518802A JP 2017530984 A5 JP2017530984 A5 JP 2017530984A5
- Authority
- JP
- Japan
- Prior art keywords
- membered
- alkyl
- composition
- group
- compound according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 0 C*(C)NC(C1CC1)=O Chemical compound C*(C)NC(C1CC1)=O 0.000 description 9
- SMNAXTKCDCNAQG-YCHJVJMSSA-N CC(C)C(/C=C(/C(N(CC1)CC1c1nc(C)cc(C(C)C)c1)=O)\N)=N Chemical compound CC(C)C(/C=C(/C(N(CC1)CC1c1nc(C)cc(C(C)C)c1)=O)\N)=N SMNAXTKCDCNAQG-YCHJVJMSSA-N 0.000 description 1
- IDHXNQZUWRNLSI-OAJVMADHSA-N CC(C)C(/C=C(/C(N(CC1)CC1c1nc(C)cc(C2CCCC2)c1)=O)\N)=N Chemical compound CC(C)C(/C=C(/C(N(CC1)CC1c1nc(C)cc(C2CCCC2)c1)=O)\N)=N IDHXNQZUWRNLSI-OAJVMADHSA-N 0.000 description 1
- WWKQLKZHPMHBSM-UHFFFAOYSA-N CC(C)[n]1nc(cccc2)c2c1 Chemical compound CC(C)[n]1nc(cccc2)c2c1 WWKQLKZHPMHBSM-UHFFFAOYSA-N 0.000 description 1
- MPBYIDFVBMROTH-UHFFFAOYSA-N CC(C)[n]1ncc(c(F)c2)c1cc2Br Chemical compound CC(C)[n]1ncc(c(F)c2)c1cc2Br MPBYIDFVBMROTH-UHFFFAOYSA-N 0.000 description 1
- QYWHLIHVMLNPCM-UHFFFAOYSA-N CC(C)c1n[nH]c(C(N(CC2)CC2c2cc(C)cc(C)n2)=O)c1 Chemical compound CC(C)c1n[nH]c(C(N(CC2)CC2c2cc(C)cc(C)n2)=O)c1 QYWHLIHVMLNPCM-UHFFFAOYSA-N 0.000 description 1
- ISYYMZGUNVIDIJ-UHFFFAOYSA-N CC(C)c1n[nH]c(C(N(CC2)CC2c2nc(C)cc(-c(cc3)ccc3C#N)c2)=O)c1 Chemical compound CC(C)c1n[nH]c(C(N(CC2)CC2c2nc(C)cc(-c(cc3)ccc3C#N)c2)=O)c1 ISYYMZGUNVIDIJ-UHFFFAOYSA-N 0.000 description 1
- PSJNUJQXRJBICQ-UHFFFAOYSA-N CC(C)c1n[nH]c(C(N(CC2)CC2c2nc(C)cc(-c(cc3)ccc3Cl)c2)=O)c1 Chemical compound CC(C)c1n[nH]c(C(N(CC2)CC2c2nc(C)cc(-c(cc3)ccc3Cl)c2)=O)c1 PSJNUJQXRJBICQ-UHFFFAOYSA-N 0.000 description 1
- JLUCSGYYDOSGIT-UHFFFAOYSA-N CC(C)c1n[nH]c(C(N(CC2)CC2c2nc(C)cc(-c(cccc3)c3Cl)c2)=O)c1 Chemical compound CC(C)c1n[nH]c(C(N(CC2)CC2c2nc(C)cc(-c(cccc3)c3Cl)c2)=O)c1 JLUCSGYYDOSGIT-UHFFFAOYSA-N 0.000 description 1
- ADOPLAZEYVDBNR-UHFFFAOYSA-N CC(C)c1n[nH]c(C(N(CC2)CC2c2nc(C)cc(-c(cccc3)c3OC)c2)=O)c1 Chemical compound CC(C)c1n[nH]c(C(N(CC2)CC2c2nc(C)cc(-c(cccc3)c3OC)c2)=O)c1 ADOPLAZEYVDBNR-UHFFFAOYSA-N 0.000 description 1
- NYBLIBCAYAWPIF-UHFFFAOYSA-N CC(C)c1n[nH]c(C(N(CC2)CC2c2nc(C)cc(-c3c[n](C(F)F)nc3)c2)=O)c1 Chemical compound CC(C)c1n[nH]c(C(N(CC2)CC2c2nc(C)cc(-c3c[n](C(F)F)nc3)c2)=O)c1 NYBLIBCAYAWPIF-UHFFFAOYSA-N 0.000 description 1
- UWUKMXRNRWPXRV-UHFFFAOYSA-N CC(C)c1n[nH]c(C(N(CC2)CC2c2nc(C)cc(-c3c[n](C)cc3)c2)=O)c1 Chemical compound CC(C)c1n[nH]c(C(N(CC2)CC2c2nc(C)cc(-c3c[n](C)cc3)c2)=O)c1 UWUKMXRNRWPXRV-UHFFFAOYSA-N 0.000 description 1
- ZMMWAYLSGNDHBJ-UHFFFAOYSA-N CC(C)c1n[nH]c(C(N(CC2)CC2c2nc(C)cc(-c3c[n](Cc4ccccc4)nc3)c2)=O)c1 Chemical compound CC(C)c1n[nH]c(C(N(CC2)CC2c2nc(C)cc(-c3c[n](Cc4ccccc4)nc3)c2)=O)c1 ZMMWAYLSGNDHBJ-UHFFFAOYSA-N 0.000 description 1
- DKUQJFPELDXTEG-UHFFFAOYSA-N CC(C)c1n[nH]c(C(N(CC2)CC2c2nc(C)cc(-c3c[o]cc3)c2)=O)c1 Chemical compound CC(C)c1n[nH]c(C(N(CC2)CC2c2nc(C)cc(-c3c[o]cc3)c2)=O)c1 DKUQJFPELDXTEG-UHFFFAOYSA-N 0.000 description 1
- AMLCZZBEFOGSRO-UHFFFAOYSA-N CC(C)c1n[nH]c(C(N(CC2)CC2c2nc(C)cc(-c3c[s]cc3)c2)=O)c1 Chemical compound CC(C)c1n[nH]c(C(N(CC2)CC2c2nc(C)cc(-c3c[s]cc3)c2)=O)c1 AMLCZZBEFOGSRO-UHFFFAOYSA-N 0.000 description 1
- FHHZGVYBDCHFED-UHFFFAOYSA-N CC(C)c1n[nH]c(C(N(CC2)CC2c2nc(C)cc(-c3cccc(C#N)c3)c2)=O)c1 Chemical compound CC(C)c1n[nH]c(C(N(CC2)CC2c2nc(C)cc(-c3cccc(C#N)c3)c2)=O)c1 FHHZGVYBDCHFED-UHFFFAOYSA-N 0.000 description 1
- ZDEOCJBDKFWTIB-UHFFFAOYSA-N CC(C)c1n[nH]c(C(N(CC2)CC2c2nc(C)cc(-c3cccc(Cl)c3)c2)=O)c1 Chemical compound CC(C)c1n[nH]c(C(N(CC2)CC2c2nc(C)cc(-c3cccc(Cl)c3)c2)=O)c1 ZDEOCJBDKFWTIB-UHFFFAOYSA-N 0.000 description 1
- GYTIXMGHYWYHPM-UHFFFAOYSA-N CC(C)c1n[nH]c(C(N(CC2)CC2c2nc(C)cc(-c3ccccc3C)c2)=O)c1 Chemical compound CC(C)c1n[nH]c(C(N(CC2)CC2c2nc(C)cc(-c3ccccc3C)c2)=O)c1 GYTIXMGHYWYHPM-UHFFFAOYSA-N 0.000 description 1
- JUGFUMWWAFDCJZ-UHFFFAOYSA-N CC(C)c1n[nH]c(C(N(CC2)CC2c2nc(C)cc(-c3cnc(C)[s]3)c2)=O)c1 Chemical compound CC(C)c1n[nH]c(C(N(CC2)CC2c2nc(C)cc(-c3cnc(C)[s]3)c2)=O)c1 JUGFUMWWAFDCJZ-UHFFFAOYSA-N 0.000 description 1
- CKMKMCGQKLICGJ-UHFFFAOYSA-N CC(C)c1n[nH]c(C(N(CC2)CC2c2nc(C)cc(-c3cnccc3)c2)=O)c1 Chemical compound CC(C)c1n[nH]c(C(N(CC2)CC2c2nc(C)cc(-c3cnccc3)c2)=O)c1 CKMKMCGQKLICGJ-UHFFFAOYSA-N 0.000 description 1
- JDIJRRHONXUUMY-BIAFCPFJSA-N CC(C)c1n[nH]c([C@@H](N(CC2)CC2c2nc(C)cc(-c(cc3)ccc3OC)c2)[O]=C)c1 Chemical compound CC(C)c1n[nH]c([C@@H](N(CC2)CC2c2nc(C)cc(-c(cc3)ccc3OC)c2)[O]=C)c1 JDIJRRHONXUUMY-BIAFCPFJSA-N 0.000 description 1
- CJNWKQKFHSMHHI-UHFFFAOYSA-N CC(C1CNC1)=O Chemical compound CC(C1CNC1)=O CJNWKQKFHSMHHI-UHFFFAOYSA-N 0.000 description 1
- NGGWJGZAKJHKSZ-UHFFFAOYSA-N CC1C=CC(C(NC)=O)=CC1 Chemical compound CC1C=CC(C(NC)=O)=CC1 NGGWJGZAKJHKSZ-UHFFFAOYSA-N 0.000 description 1
- ZHJJLMNCPIHBRM-UHFFFAOYSA-N CC1C=Cc2n[n](C)cc2C1F Chemical compound CC1C=Cc2n[n](C)cc2C1F ZHJJLMNCPIHBRM-UHFFFAOYSA-N 0.000 description 1
- FJXRIACJPBCMCU-JOAIZHEFSA-O CCN/C=C(\C=[NH2+])/c1cc(C(CC2)CN2C(c2cc(C(C)C)n[nH]2)=O)nc(C)c1 Chemical compound CCN/C=C(\C=[NH2+])/c1cc(C(CC2)CN2C(c2cc(C(C)C)n[nH]2)=O)nc(C)c1 FJXRIACJPBCMCU-JOAIZHEFSA-O 0.000 description 1
- GQJXSYYQPWIJOU-ZNDRMEFZSA-N CCc1cc(C(CC2)CN2C(/C(/N)=C/C(C(C)C)=N)=O)nc(C)c1 Chemical compound CCc1cc(C(CC2)CN2C(/C(/N)=C/C(C(C)C)=N)=O)nc(C)c1 GQJXSYYQPWIJOU-ZNDRMEFZSA-N 0.000 description 1
- YCDDKKGCWDMJKY-SSDOTTSWSA-N CNC(C(C1)=CC=C[C@H]1I)=O Chemical compound CNC(C(C1)=CC=C[C@H]1I)=O YCDDKKGCWDMJKY-SSDOTTSWSA-N 0.000 description 1
- TZAYNGPUOOUEAP-UHFFFAOYSA-N C[n]1nc(C(F)(F)F)c(Br)c1 Chemical compound C[n]1nc(C(F)(F)F)c(Br)c1 TZAYNGPUOOUEAP-UHFFFAOYSA-N 0.000 description 1
- WQYAKZVLTOWKQB-UHFFFAOYSA-N C[n]1ncc(cc2)c1nc2Cl Chemical compound C[n]1ncc(cc2)c1nc2Cl WQYAKZVLTOWKQB-UHFFFAOYSA-N 0.000 description 1
- CSUGQXMRKOKBFI-UHFFFAOYSA-N C[n]1ncc2ccccc12 Chemical compound C[n]1ncc2ccccc12 CSUGQXMRKOKBFI-UHFFFAOYSA-N 0.000 description 1
- HUMNYLRZRPPJDN-UHFFFAOYSA-N O=Cc1ccccc1 Chemical compound O=Cc1ccccc1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2014088309 | 2014-10-10 | ||
| CNPCT/CN2014/088309 | 2014-10-10 | ||
| PCT/US2015/054949 WO2016057924A1 (en) | 2014-10-10 | 2015-10-09 | Pyrrolidine amide compounds as histone demethylase inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017530984A JP2017530984A (ja) | 2017-10-19 |
| JP2017530984A5 true JP2017530984A5 (enExample) | 2018-11-22 |
| JP6783230B2 JP6783230B2 (ja) | 2020-11-11 |
Family
ID=54337935
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017518802A Expired - Fee Related JP6783230B2 (ja) | 2014-10-10 | 2015-10-09 | ヒストンデメチラーゼのインヒビターとしてのピロリドンアミド化合物 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US10022354B2 (enExample) |
| EP (1) | EP3204379B1 (enExample) |
| JP (1) | JP6783230B2 (enExample) |
| CN (1) | CN107912040B (enExample) |
| WO (1) | WO2016057924A1 (enExample) |
Families Citing this family (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR102017010009A2 (pt) | 2016-05-27 | 2017-12-12 | Gilead Sciences, Inc. | Compounds for the treatment of hepatitis b virus infection |
| ES2969239T3 (es) | 2016-05-27 | 2024-05-17 | Gilead Sciences Inc | Combinación de ledipasvir y sofosbuvir para su uso en el tratamiento de infecciones por el virus de la hepatitis B en humanos |
| JOP20190024A1 (ar) | 2016-08-26 | 2019-02-19 | Gilead Sciences Inc | مركبات بيروليزين بها استبدال واستخداماتها |
| KR102268448B1 (ko) | 2016-09-02 | 2021-06-22 | 길리애드 사이언시즈, 인코포레이티드 | 톨 유사 수용체 조정제 화합물 |
| ES2826748T3 (es) | 2016-09-02 | 2021-05-19 | Gilead Sciences Inc | Derivados de 4,6-diamino-pirido[3,2-d]pirimidina como moduladores de receptores de tipo Toll |
| MA46535A (fr) | 2016-10-14 | 2019-08-21 | Prec Biosciences Inc | Méganucléases modifiées spécifiques de séquences de reconnaissance dans le génome du virus de l'hépatite b |
| TW201822637A (zh) | 2016-11-07 | 2018-07-01 | 德商拜耳廠股份有限公司 | 用於控制動物害蟲的經取代磺醯胺類 |
| MX393780B (es) | 2017-01-17 | 2025-03-24 | Heparegenix Gmbh | Inhibidores de proteina cinasa para promover la regeneracion hepatica o reducir o prevenir la muerte de hepatocitos |
| TWI868958B (zh) | 2017-01-31 | 2025-01-01 | 美商基利科學股份有限公司 | 替諾福韋埃拉酚胺(tenofovir alafenamide)之晶型 |
| JOP20180008A1 (ar) | 2017-02-02 | 2019-01-30 | Gilead Sciences Inc | مركبات لعلاج إصابة بعدوى فيروس الالتهاب الكبدي b |
| JOP20180040A1 (ar) | 2017-04-20 | 2019-01-30 | Gilead Sciences Inc | مثبطات pd-1/pd-l1 |
| KR20190063745A (ko) * | 2017-11-30 | 2019-06-10 | (주)인핸스드바이오 | p34 단백질 및 NEDD4-1 단백질의 결합 억제제로서의 신규 화합물 및 이의 용도 |
| CN111511754B (zh) | 2017-12-20 | 2023-09-12 | 捷克共和国有机化学与生物化学研究所 | 活化sting转接蛋白的具有膦酸酯键的2’3’环状二核苷酸 |
| EP3728283B1 (en) | 2017-12-20 | 2023-11-22 | Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. | 3'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein |
| WO2019160882A1 (en) | 2018-02-13 | 2019-08-22 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
| KR102526964B1 (ko) | 2018-02-26 | 2023-04-28 | 길리애드 사이언시즈, 인코포레이티드 | Hbv 복제 억제제로서의 치환된 피롤리진 화합물 |
| WO2019195181A1 (en) | 2018-04-05 | 2019-10-10 | Gilead Sciences, Inc. | Antibodies and fragments thereof that bind hepatitis b virus protein x |
| TW202005654A (zh) | 2018-04-06 | 2020-02-01 | 捷克科學院有機化學與生物化學研究所 | ２，２，─環二核苷酸 |
| TWI833744B (zh) | 2018-04-06 | 2024-03-01 | 捷克科學院有機化學與生物化學研究所 | 3'3'-環二核苷酸 |
| TWI818007B (zh) | 2018-04-06 | 2023-10-11 | 捷克科學院有機化學與生物化學研究所 | 2'3'-環二核苷酸 |
| TW201945388A (zh) | 2018-04-12 | 2019-12-01 | 美商精密生物科學公司 | 對b型肝炎病毒基因體中之識別序列具有特異性之最佳化之經工程化巨核酸酶 |
| WO2019204609A1 (en) | 2018-04-19 | 2019-10-24 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
| US20190359645A1 (en) | 2018-05-03 | 2019-11-28 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3'-cyclic dinucleotides comprising carbocyclic nucleotide |
| BR112020026746A2 (pt) | 2018-07-13 | 2021-03-30 | Gilead Sciences, Inc. | Composto, composição farmacêutica, métodos para inibir pd-1, pd-l1 e/ou a interação de pd-1/pd-l1 e para tratar câncer, e, kit para tratar ou prevenir câncer ou uma doença ou condição. |
| WO2020028097A1 (en) | 2018-08-01 | 2020-02-06 | Gilead Sciences, Inc. | Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid |
| US12117426B2 (en) * | 2018-09-10 | 2024-10-15 | Shimadzu Corporation | Biological membrane phosphoinositide separation method |
| CN112955435B (zh) | 2018-10-24 | 2024-09-06 | 吉利德科学公司 | Pd-1/pd-l1抑制剂 |
| FI3873903T3 (fi) | 2018-10-31 | 2024-03-26 | Gilead Sciences Inc | Substituoituja 6-azabentsiimidatsoliyhdisteitä HPK1-inhibiittoreina |
| KR102658602B1 (ko) | 2018-10-31 | 2024-04-19 | 길리애드 사이언시즈, 인코포레이티드 | Hpk1 억제 활성을 갖는 치환된 6-아자벤즈이미다졸 화합물 |
| CN109852662B (zh) * | 2018-12-25 | 2021-02-19 | 华南农业大学 | 组蛋白甲基化H3K4me3在猪卵巢颗粒细胞中的应用 |
| EP3935065A1 (en) | 2019-03-07 | 2022-01-12 | Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. | 3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator |
| CA3129011C (en) | 2019-03-07 | 2023-12-19 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3'-cyclic dinucleotides and prodrugs thereof |
| EP3934757B1 (en) | 2019-03-07 | 2023-02-22 | Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. | 2'3'-cyclic dinucleotides and prodrugs thereof |
| TWI751517B (zh) | 2019-04-17 | 2022-01-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| TW202210480A (zh) | 2019-04-17 | 2022-03-16 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| TWI826690B (zh) | 2019-05-23 | 2023-12-21 | 美商基利科學股份有限公司 | 經取代之烯吲哚酮化物及其用途 |
| MX2021015452A (es) | 2019-06-25 | 2022-02-11 | Gilead Sciences Inc | Proteinas de fusion flt3l-fc y metodos de uso. |
| US20220289751A1 (en) * | 2019-07-17 | 2022-09-15 | Ono Pharmaceutical Co., Ltd. | Compound having kdm5 inhibitory activity and pharmaceutical use thereof |
| WO2021011891A1 (en) | 2019-07-18 | 2021-01-21 | Gilead Sciences, Inc. | Long-acting formulations of tenofovir alafenamide |
| WO2021034804A1 (en) | 2019-08-19 | 2021-02-25 | Gilead Sciences, Inc. | Pharmaceutical formulations of tenofovir alafenamide |
| KR20220074917A (ko) | 2019-09-30 | 2022-06-03 | 길리애드 사이언시즈, 인코포레이티드 | Hbv 백신 및 hbv를 치료하는 방법 |
| AR120324A1 (es) * | 2019-10-29 | 2022-02-09 | Biogen Ma Inc | Inhibidores de o-glucoproteína-2-acetamido-2-deoxi-3-d-glucopiranosidasa espirocíclica |
| DK4069729T3 (da) | 2019-12-06 | 2025-04-07 | Prec Biosciences Inc | Optimerede, modificerede meganukleaser med specificitet for en genkendelsessekvens i hepatitis b-virusgenomet |
| NZ790364A (en) * | 2020-01-29 | 2025-12-19 | Kamari Pharma Ltd | Compounds and compositions for use in treating skin disorders |
| CN111138289B (zh) * | 2020-02-27 | 2022-08-30 | 奥锐特药业(天津)有限公司 | 一种化合物及使用该化合物合成5-乙酰基-1h-吡唑-3-羧酸的工艺 |
| US12552806B2 (en) | 2020-03-20 | 2026-02-17 | University Of Southern California | Androgen receptor regulation by small molecule enantiomers |
| AR121620A1 (es) | 2020-03-20 | 2022-06-22 | Gilead Sciences Inc | Profármacos de nucleósidos 4-c-sustituidos-2-halo-2-deoxiadenosina y métodos de preparación y uso de los mismos |
| EP4471027A1 (en) | 2020-05-07 | 2024-12-04 | ONO Pharmaceutical Co., Ltd. | 3-azabicyclo(3.1.0)hexane derivatives having kdm5 inhibitory activity and use thereof |
| JP7712352B2 (ja) | 2020-08-07 | 2025-07-23 | ギリアード サイエンシーズ， インコーポレイテッド | ホスホンアミドヌクレオチド類似体のプロドラッグ及びその薬学的使用 |
| TW202406932A (zh) | 2020-10-22 | 2024-02-16 | 美商基利科學股份有限公司 | 介白素2-Fc融合蛋白及使用方法 |
| US20230391752A1 (en) * | 2020-10-22 | 2023-12-07 | Chulalongkorn University | Pyrrolidine-3-carboxamide derivatives and related uses |
| EP4337223A1 (en) | 2021-05-13 | 2024-03-20 | Gilead Sciences, Inc. | Combination of a tlr8 modulating compound and anti-hbv sirna therapeutics |
| KR20240005901A (ko) | 2021-06-23 | 2024-01-12 | 길리애드 사이언시즈, 인코포레이티드 | 디아실글리세롤 키나제 조절 화합물 |
| AU2022299051B2 (en) | 2021-06-23 | 2025-03-13 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| KR20240025616A (ko) | 2021-06-23 | 2024-02-27 | 길리애드 사이언시즈, 인코포레이티드 | 다이아실글리세롤 키나제 조절 화합물 |
| AU2022298639C1 (en) | 2021-06-23 | 2025-07-17 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| JP7743829B2 (ja) * | 2021-11-05 | 2025-09-25 | 小野薬品工業株式会社 | Ｋｄｍ５阻害作用を有する化合物を含有する医薬組成物 |
| TWI907744B (zh) * | 2021-11-05 | 2025-12-11 | 日商小野藥品工業股份有限公司 | 包含具有kdm5抑制活性之化合物之醫藥組合物 |
| CN120187416A (zh) | 2022-11-11 | 2025-06-20 | 阿斯利康(瑞典)有限公司 | 用于治疗癌症的组合疗法 |
| CN116284202B (zh) * | 2023-03-28 | 2024-07-02 | 华侨大学 | 白桦脂酸的PROTACs化合物及其制备方法和应用 |
| WO2025240244A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies comprising bulevirtide and lonafarnib for use in the treatment of hepatitis d virus infection |
| WO2025240242A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies with ribavirin |
| WO2025240246A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies with ribavirin |
| US20250345389A1 (en) | 2024-05-13 | 2025-11-13 | Gilead Sciences, Inc. | Combination therapies |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CU22545A1 (es) | 1994-11-18 | 1999-03-31 | Centro Inmunologia Molecular | Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico |
| US4943533A (en) | 1984-03-01 | 1990-07-24 | The Regents Of The University Of California | Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor |
| AU639726B2 (en) | 1989-09-08 | 1993-08-05 | Duke University | Structural alterations of the egf receptor gene in human gliomas |
| AU661533B2 (en) | 1992-01-20 | 1995-07-27 | Astrazeneca Ab | Quinazoline derivatives |
| GB9314893D0 (en) | 1993-07-19 | 1993-09-01 | Zeneca Ltd | Quinazoline derivatives |
| EP0659439B1 (en) | 1993-12-24 | 2001-10-24 | MERCK PATENT GmbH | Immunoconjugates |
| US5654307A (en) | 1994-01-25 | 1997-08-05 | Warner-Lambert Company | Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family |
| IL112248A0 (en) | 1994-01-25 | 1995-03-30 | Warner Lambert Co | Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them |
| IL112249A (en) | 1994-01-25 | 2001-11-25 | Warner Lambert Co | Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds |
| CN1068323C (zh) | 1994-07-21 | 2001-07-11 | 阿克佐诺贝尔公司 | 环酮过氧化物配制剂 |
| US5804396A (en) | 1994-10-12 | 1998-09-08 | Sugen, Inc. | Assay for agents active in proliferative disorders |
| DE69522717T2 (de) | 1995-03-30 | 2002-02-14 | Pfizer Inc., New York | Chinazolinderivate |
| GB9508538D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
| GB9508565D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quiazoline derivative |
| US5747498A (en) | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
| EP0831880A4 (en) | 1995-06-07 | 2004-12-01 | Imclone Systems Inc | ANTIBODIES AND FRAGMENTS OF ANTIBODIES INHIBITING TUMOR GROWTH |
| ATE212993T1 (de) | 1995-07-06 | 2002-02-15 | Novartis Erfind Verwalt Gmbh | Pyrolopyrimidine und verfahren zu ihrer herstellung |
| US5760041A (en) | 1996-02-05 | 1998-06-02 | American Cyanamid Company | 4-aminoquinazoline EGFR Inhibitors |
| GB9603095D0 (en) | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline derivatives |
| HU228446B1 (en) | 1996-04-12 | 2013-03-28 | Warner Lambert Co | Kinazoline derivatives as irreversible inhibitors of protein-kinase, pharmaceutical compositions containing these compounds and use thereof |
| JP4386967B2 (ja) | 1996-07-13 | 2009-12-16 | グラクソ、グループ、リミテッド | プロテインチロシンキナーゼ阻害剤としての縮合複素環式化合物 |
| ID18494A (id) | 1996-10-02 | 1998-04-16 | Novartis Ag | Turunan pirazola leburan dan proses pembuatannya |
| US6002008A (en) | 1997-04-03 | 1999-12-14 | American Cyanamid Company | Substituted 3-cyano quinolines |
| UA73073C2 (uk) | 1997-04-03 | 2005-06-15 | Уайт Холдінгз Корпорейшн | Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція |
| US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
| EP0980244B1 (en) | 1997-05-06 | 2003-06-04 | Wyeth Holdings Corporation | Use of quinazoline compounds for the treatment of polycystic kidney disease |
| ZA986729B (en) | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitors of tyrosine kinases |
| ZA986732B (en) | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitiors of tyrosine kinases |
| TW436485B (en) | 1997-08-01 | 2001-05-28 | American Cyanamid Co | Substituted quinazoline derivatives |
| KR20010031813A (ko) | 1997-11-06 | 2001-04-16 | 윌리암 에이취 캘넌, 에곤 이 버그 | 결장 폴립 치료용 티로신 키나제 억제제로서의 퀴나졸린유도체의 용도 |
| EP1131304B1 (en) | 1998-11-19 | 2002-12-04 | Warner-Lambert Company | N- 4-(3-chloro-4-fluoro-phenylamino)-7-(3-morpholin-4-yl-propoxy)-quinazolin-6-yl]-acrylamide, an irreversible inhibitor of tyrosine kinases |
| CN102171204B (zh) * | 2008-10-02 | 2014-08-20 | 旭化成制药株式会社 | 8位取代异喹啉衍生物及其用途 |
| US8513244B2 (en) * | 2011-05-31 | 2013-08-20 | Theravance, Inc. | Neprilysin inhibitors |
| BR112014026176A2 (pt) * | 2012-05-22 | 2017-06-27 | Hoffmann La Roche | dipiridilaminas substituídas e usos das mesmas |
| EP2920171B1 (en) * | 2012-11-16 | 2018-08-29 | Merck Sharp & Dohme Corp. | Purine inhibitors of human phosphatidylinositol 3-kinase delta |
| EP2968282B1 (en) * | 2013-03-12 | 2018-05-09 | Celgene Quanticel Research, Inc. | Histone dementhylase inhibitors |
| EP2970307B1 (en) * | 2013-03-13 | 2020-03-11 | Genentech, Inc. | Pyrazolo compounds and uses thereof |
-
2015
- 2015-10-09 CN CN201580066844.9A patent/CN107912040B/zh not_active Expired - Fee Related
- 2015-10-09 EP EP15784257.6A patent/EP3204379B1/en active Active
- 2015-10-09 WO PCT/US2015/054949 patent/WO2016057924A1/en not_active Ceased
- 2015-10-09 JP JP2017518802A patent/JP6783230B2/ja not_active Expired - Fee Related
-
2017
- 2017-04-07 US US15/482,584 patent/US10022354B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017530984A5 (enExample) | ||
| JP2018505169A5 (enExample) | ||
| JP2018510851A5 (enExample) | ||
| RU2016110096A (ru) | Новое хинолин-замещенное соединение | |
| JP2017528524A5 (enExample) | ||
| JP2016529312A5 (enExample) | ||
| JP2019510832A5 (enExample) | ||
| JP2017518334A5 (enExample) | ||
| JP2019516759A5 (enExample) | ||
| JP2018525441A5 (enExample) | ||
| RU2013137452A (ru) | Композиции, содержащие расщепляемое ферментами пролекарство оксикодона | |
| JP2016516020A5 (enExample) | ||
| JP2016539134A5 (enExample) | ||
| RU2014135436A (ru) | Комбинация ингибитора rtk с антиэстрогеном и ее применение для лечения рака | |
| JP2017101088A (ja) | 選択的アンドロゲン受容体モジュレーター（ｓａｒｍ）によりアンドロゲン受容体（ａｒ）陽性乳癌を処置する方法 | |
| JP2009504764A5 (enExample) | ||
| JP2015500209A5 (enExample) | ||
| JP2015518004A5 (enExample) | ||
| JP2013510123A5 (enExample) | ||
| JP2020506951A5 (enExample) | ||
| JP2017141277A5 (enExample) | ||
| JP2014511383A5 (enExample) | ||
| JP2014505107A5 (enExample) | ||
| JP2016515110A5 (enExample) | ||
| RU2019141734A (ru) | Терапевтические соединения и композиции и способы их применения |